New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
19:56 EDTHZNPHorizon presents data showing effectiveness of RAYOS
Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, CAPRA-2, clinical trial demonstrating that patients with active rheumatoid arthritis (RA) treated with its recently approved RAYOS 5 mg (prednisone) delayed-release tablets had a significant improvement in reduction of fatigue, as determined by the Functional Assessment of Chronic Illness Therapy - Fatigue, FACIT-F, questionnaire. Data were presented during the American College of Rheumatology, ACR/Association of Rheumatology Health Professionals,ARHP, Annual Scientific Meeting in Washington, D.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
08:07 EDTHZNPHorizon Pharma announces POZEN issued U.S. patent covering VIMOVO
Horizon Pharma (HZNP) announced that POZEN (POZN), has received from the United States Patent and Trademark Office a Notice of Allowance for U.S. patent application number 12/822,612, entitled "Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer" that relates to VIMOVO delayed release tablets in patients taking low dose aspirin. After issuance, Horizon and POZEN plan to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
September 26, 2014
09:09 EDTHZNPHorizon reports executive committee, commercial restructuring
Subscribe for More Information
September 23, 2014
17:02 EDTHZNPBalaji Venkataraman reports 15.6% stake in Horizon Pharma
Subscribe for More Information
07:54 EDTHZNPLeerink to hold a conference
Subscribe for More Information
September 19, 2014
16:57 EDTHZNPHorizon Pharma files automatic ordinary share shelf
10:46 EDTHZNPHorizon Pharma backs FY15 revenue view $380M-$405M, consensus $376.94M
Backs FYT15 adjusted EBITDA view $150M-$170M
10:45 EDTHZNPHorizon Pharma backs FY14 revenue view $270M-$280M, consensus $277.56M
Subscribe for More Information
September 18, 2014
19:50 EDTHZNPHorizon Pharma trading halted, pending news
Subscribe for More Information
09:19 EDTHZNPHorizon Pharma announces holder approval of Vidara acquisition
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use